调肝理脾方抗酒精性肝纤维化作用机制研究  

Mechanism of Tiaogan Lipi prescription on alcohol hepatic fibrosis

作　　者：李丰衣[1] 孙劲晖[2] 田德禄[2] 祝世功[3] 潘慧[3] 刘霞[4] 王庆宝[5] 

机构地区：[1]中国人民解放军第三○二医院,北京100039 [2]北京中医药大学东直门医院,北京100700 [3]北京大学医学部,北京100083 [4]卫生部中日友好医院,北京100029 [5]泰山医学院,山东泰安271016

出　　处：《山东中医药大学学报》2009年第3期250-252,共3页Journal of Shandong University of Traditional Chinese Medicine

基　　金：山东省自然科学基金项目(编号:Q2005C04)

摘　　要：目的:探讨调肝理脾方对实验性酒精性肝纤维化模型大鼠的抑制作用及作用机制。方法:Wistar雄性大鼠以"白酒-吡唑-玉米油"混合液灌胃16周制备酒精性肝纤维化模型,将存活大鼠随机分成4组:模型组、中药(调肝理脾方)治疗组、西药(安珐特)对照组和中药(复方鳖甲软肝片)对照组,另设正常组,分别给予相应药物和生理盐水。4周后,经HE染色、Mallory染色和转化生长因子-β1(TGF-β1)蛋白表达免疫组化染色,光镜观察大鼠肝组织病理学变化。结果:调肝理脾方能显著降低大鼠肝组织纤维化程度,下调大鼠肝组织中TGF-β1蛋白含量。结论:病理学实验研究证实调肝理脾方能有效阻止和逆转酒精性肝纤维化的进程。Objective： To probe into the inhibiting action and the potential mechanism of Tiaogan Lipi prescription on alcohol hepatic fibrosis. Methods： Wistar male rats were administered by intragastrical perfusion by some mixture of＂alcohol-Pyrazole-corn oil＂ for 16 weeks. The survivals were randomly divided into four groups： model control group, therapic group of TCM（Tiaoganlipi prescription）, control group of western medicine（compound embryonic bovine liver extract tablets） and a control group of TCM（compound Biejia Ruangan tablets）. Another group was the blank group. All rats were administered with corresponding medicines and normal sodium. Mter 4 weeks＇ intervention, all rats were stained with HE, Mallory and TGF-β1 protein immunohistochemical methods, then the hepatic histopathological change in rats with hepatic fibrosis were observed by light microscope. Results： Tiaogan Lipi prescription significantly decreased the level of the hepatic fibrosis and depressed the expression of TGF-β1 in hepatic tissue of hepatic fibrosis rats. Conclusion： The pathological experiment confirmed that Tiaogan Lipi prescription effectively inhibited and revesed the process of alcoholic hepatic fibrosis.

关 键 词：调肝理脾方 酒精性肝纤维化 免疫组织化学染色 TGF-Β 1蛋白表达 大鼠 

分 类 号：R259.752[医药卫生—中西医结合]